Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Amgen is the lead sponsor of 104 current clinical trials in our USA, China, UK, Ireland, India and EU (CTIS) registers. 42 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Maridebart cafraglutide, Tarlatamab and Inebilizumab. The most-studied condition is Obesity.

Company profiles on this site (news, sites, medicines, approvals): Amgen Ireland (IE) →Amgen (US) →

ClinicalTrials.gov trials by status

Recruiting4245%
Not yet open22%
Active, closed4953%

Trials by phase

Phase 34346%
Phase 12426%
Phase 21314%
Phase 466%
Phase 1/244%
Observational33%

Clinical trials sponsored by Amgen

93 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer NCT07213674 · Metastatic Castration-resistant Prostate Cancer Drugs: Abiraterone acetate, Cabazitaxel, Docetaxel	Phase 3	Recruiting	2025-11	UK, USA
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity NCT07037433 · Atherosclerotic Cardiovascular Disease, Overweight, Obesity Drug: Maridebart cafraglutide	Phase 3	Recruiting	2025-07	UK, USA, China
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) NCT06747949 · Sjögren's Syndrome Drug: Dazodalibep	Phase 3	Recruiting	2025-02	UK, USA
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis NCT04804553 · Active Juvenile Psoriatic Arthritis Drug: Apremilast	Phase 3	Recruiting	2022-03	UK
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer NCT07493512 · Metastatic Castration-resistant Prostate Cancer (mCRPC) Drug: Xaluritamig	Phase 1	Recruiting	2026-04	USA
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration NCT07614776 · Neovascular Age-related Macular Degeneration, nAMD	Phase 3	Recruiting	2026-05	USA
A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis NCT03633708 · ClinicalTrials.gov ↗ · Secondary Hyperparathyroidism, Chronic Kidney Disease Drug: Etelcalcetide	Phase 3	Recruiting	2019-04	USA, India
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity NCT07037459 · ClinicalTrials.gov ↗ · Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity Drug: Maridebart cafraglutide	Phase 3	Recruiting	2025-06	UK, USA, China
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer NCT04221542 · Prostate Cancer Drugs: Abiraterone, Enzalutamide, Xaluritamig	Phase 1	Recruiting	2020-03	USA, China
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS) NCT07297979 · Ewing Sarcoma Drug: Xaluritamig	Phase 1	Recruiting	2026-04	USA
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors NCT07094113 · ClinicalTrials.gov ↗ · KRAS Altered Advanced or Metastatic Solid Tumors Drugs: Panitumumab, Pembrolizumab	Phase 1	Recruiting	2025-07	UK, USA, China
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight NCT07441252 · Overweight or Obesity and Elevated Liver Fat Drug: Maridebart cafraglutide	Phase 2	Recruiting	2026-03	USA
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation NCT06252649 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer Drugs: Bevacizumab-awwb, Folfiri, Mvasi	Phase 3	Recruiting	2024-07	UK, USA, China
Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC) NCT07778316 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Drug: Tarlatamab	Phase 3	Recruiting	2026-08	USA, China
A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus NCT07590193 · Diabetes Mellitus, Type 2	Phase 1	Recruiting	2026-06	USA
Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder NCT05549258 · ClinicalTrials.gov ↗ · Neuromyelitis Optica Spectrum Disorder Drug: Inebilizumab	Phase 2	Recruiting	2023-07	UK, USA
A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis NCT03969329 · ClinicalTrials.gov ↗ · Secondary Hyperparathyroidism Drug: Etelcalcetide	Phase 3	Recruiting	2019-12	UK
Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease NCT04528082 · ClinicalTrials.gov ↗ · Behçet Disease Drug: Apremilast	Phase 3	Recruiting	2021-09	UK
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases NCT06570798 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis Drugs: Blinatumomab, Inebilizumab	Phase 2	Recruiting	2025-07	UK, USA
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors NCT07403721 · ClinicalTrials.gov ↗ · Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)	Phase 1	Recruiting	2026-04	USA, China
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) NCT05920356 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer (NSCLC) Drugs: Pembrolizumab, Sotorasib	Phase 3	Recruiting	2023-11	UK, USA, China
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) NCT07531095 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Drugs: Durvalumab, Tarlatamab, ZL-1310	Phase 1	Recruiting	2026-04	USA
Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy NCT05909761 · ClinicalTrials.gov ↗ · Neuromyelitis Optica Spectrum Disorder, Pregnancy Related Drug: Uplizna	Observational	Recruiting	2026-10	USA
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION) NCT07684235 · ClinicalTrials.gov ↗ · Obesity, Overweight Drug: Maridebart cafraglutide	Phase 3	Recruiting	2026-07	USA
A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP) NCT07700238 · ClinicalTrials.gov ↗ · Primary Immune Thrombocytopenia Drug: Romiplostim	Phase 3	Recruiting	2026-08	USA
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG) NCT06987539 · ClinicalTrials.gov ↗ · Generalized Myasthenia Gravis Drug: Inebilizumab	Phase 2	Recruiting	2026-07	USA
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) NCT07037758 · ClinicalTrials.gov ↗ · Extensive Stage Small Cell Lung Cancer Drugs: Etakafusp alfa, Tarlatamab	Phase 1	Recruiting	2025-09	USA
An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease NCT07438405 · ClinicalTrials.gov ↗ · Thyroid Eye Disease Drug: AMG 732	Phase 2	Recruiting	2026-05	USA
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) NCT06598306 · ClinicalTrials.gov ↗ · Extensive Stage Small Cell Lung Cancer Drug: Tarlatamab	Phase 1	Recruiting	2024-10	USA, China
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH) NCT07575399 · ClinicalTrials.gov ↗ · Obesity or Overweight Drug: Maridebart cafraglutide	Phase 3	Recruiting	2026-05	USA
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events NCT07136012 · ClinicalTrials.gov ↗ · Cardiovascular Disease Drug: Olpasiran	Phase 3	Recruiting	2025-08	USA
A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese Volunteers NCT07745907 · ClinicalTrials.gov ↗ · Healthy Participants Drug: AMG 691	Phase 1	Recruiting	2026-08	USA
Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta NCT07366086 · ClinicalTrials.gov ↗ · Osteogenesis Imperfecta	Phase 3	Recruiting	2026-03	USA
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer NCT07140900 · ClinicalTrials.gov ↗ · Metastatic Hormone-sensitive Prostate Cancer (mHSPC) Drugs: Abiraterone, Darolutamide, Xaluritamig	Phase 1	Recruiting	2025-10	USA
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) NCT07684144 · ClinicalTrials.gov ↗ · Obesity, Overweight, Diabetes Mellitus, Type 2 Drug: Maridebart cafraglutide	Phase 3	Recruiting	2026-07	USA
Aimovig Pregnancy Exposure Registry NCT06150781 · ClinicalTrials.gov ↗ · Migraine	Observational	Recruiting	2021-01	USA
A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout NCT07388498 · ClinicalTrials.gov ↗ · Uncontrolled Gout Drug: Methotrexate	Phase 3	Recruiting	2026-02	USA
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy NCT07226765 · ClinicalTrials.gov ↗ · Obstructive Sleep Apnea Drug: Maridebart cafraglutide	Phase 3	Recruiting	2025-11	USA
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial NCT07293260 · ClinicalTrials.gov ↗ · Cardiovascular Disease Drug: Olpasiran	Phase 3	Recruiting	2026-03	USA, China
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis NCT06072482 · ClinicalTrials.gov ↗ · Antineutrophil Cytoplasmic Antibody-associated Vasculitis Drug: Avacopan	Phase 4	Recruiting	2024-02	USA
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer NCT06613100 · ClinicalTrials.gov ↗ · Prostate Cancer Drug: Xaluritamig	Phase 1	Recruiting	2024-11	USA
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation NCT07172919 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Drugs: Panitumumab, Sotorasib	Phase 2	Recruiting	2026-01	USA
A Trial of Inebilizumab in Participants With Autoimmune Hepatitis NCT07598825 · ClinicalTrials.gov ↗ · Autoimmune Hepatitis, AIH Drug: Inebilizumab	Phase 3	Not yet open	2026-09	USA, China
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD NCT07222553 · ClinicalTrials.gov ↗ · Immunoglobulin G4-related Disease Drug: Inebilizumab	Phase 2	Not yet open	2026-10	USA, China
A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China NCT06588153 · Glucocorticoid-induced Osteoporosis Drugs: Denosumab, Prolia	Phase 4	Active, closed	2025-05	China
Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China NCT06332014 · Osteoporosis Drug: Prolia	Phase 4	Active, closed	2024-08	China
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer NCT06311721 · Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Drug: Pembrolizumab	Phase 3	Active, closed	2024-09	UK, USA
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab NCT06211036 · Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer Drugs: Durvalumab, Tarlatamab	Phase 3	Active, closed	2024-06	Ireland, USA, China
A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM) NCT06660173 · Type 2 Diabetes Mellitus (T2DM) Drug: Maridebart cafraglutide	Phase 2	Active, closed	2024-11	USA
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC NCT06745323 · Small Cell Lung Cancer (SCLC) Drug: Tarlatamab	Phase 2	Active, closed	2025-02	UK, USA, China
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease NCT04540497 · ClinicalTrials.gov ↗ · IgG4 Related Disease Drug: Inebilizumab	Phase 3	Active, closed	2020-12	Ireland, UK, USA, India, China
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer NCT05740566 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer (SCLC) Drugs: Amrubicin, Lurbinectedin, Tarlatamab	Phase 3	Active, closed	2023-05	Ireland, UK, USA, China
Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC) NCT03319940 · Small Cell Lung Carcinoma Drugs: Pembrolizumab, Tarlatamab	Phase 1	Active, closed	2017-12	UK, USA
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta NCT05972551 · Osteogenesis Imperfecta Drug: Romosozumab	Phase 3	Active, closed	2024-04	UK, USA, China
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight NCT06858839 · Obesity Drug: Maridebart cafraglutide	Phase 3	Active, closed	2025-03	UK, USA
Myasthenia Gravis Inebilizumab Trial NCT04524273 · ClinicalTrials.gov ↗ · Myasthenia Gravis Drug: Inebilizumab	Phase 3	Active, closed	2020-10	USA, India, China
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight NCT06858878 · ClinicalTrials.gov ↗ · Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight Drug: Maridebart cafraglutide	Phase 3	Active, closed	2025-03	UK, USA
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State NCT06245408 · ClinicalTrials.gov ↗ · Sjögren's Syndrome (SS) Drug: Dazodalibep	Phase 3	Active, closed	2024-04	UK, USA
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction NCT05284747 · Cardiovascular Disease, Myocardial Infarction, Stroke Drug: Evolocumab	Phase 4	Active, closed	2022-10	USA
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) NCT06117774 · ClinicalTrials.gov ↗ · Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer Drug: Tarlatamab	Phase 3	Active, closed	2024-02	UK, USA, China
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial NCT05581303 · ClinicalTrials.gov ↗ · Atherosclerotic Cardiovascular Disease Drug: Olpasiran	Phase 3	Active, closed	2022-12	UK, USA, China
A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) NCT05094336 · ClinicalTrials.gov ↗ · Advanced MTAP-null Solid Tumors Drugs: Anvumetostat, Docetaxel	Phase 1/2	Active, closed	2022-02	UK, USA, China
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) NCT04185883 · ClinicalTrials.gov ↗ · Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation Drugs: Afatinib, Atezolizumab, Bevacizumab-awwb	Phase 1	Active, closed	2019-12	UK, USA
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia NCT04994717 · ClinicalTrials.gov ↗ · Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) Drug: Blinatumomab	Phase 3	Active, closed	2021-11	UK, USA, China
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma NCT06637371 · ClinicalTrials.gov ↗ · Asthma Drug: AMG 691	Phase 1	Active, closed	2024-10	UK, USA
Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) NCT06054113 · ClinicalTrials.gov ↗ · B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia	Phase 2	Active, closed	2024-07	China
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) NCT06691984 · ClinicalTrials.gov ↗ · Metastatic Castration-resistant Prostate Cancer Drugs: Abiraterone, Cabazitaxel, Enzalutamide	Phase 3	Active, closed	2024-12	UK, USA
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine NCT03836040 · ClinicalTrials.gov ↗ · Migraine	Phase 3	Active, closed	2019-07	UK, USA
Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV. NCT06321601 · ClinicalTrials.gov ↗ · Vasculitis Drug: Avacopan	Phase 3	Active, closed	2024-10	USA
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103) NCT06360354 · ClinicalTrials.gov ↗ · Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers Drugs: Anvumetostat, Gemcitabine, Modified FOLFIRINOX	Phase 1	Active, closed	2024-05	UK, USA, China
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201) NCT06593522 · ClinicalTrials.gov ↗ · MTAP-deleted NSCLC Drug: Anvumetostat	Phase 2	Active, closed	2024-12	USA, China
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease NCT06248619 · ClinicalTrials.gov ↗ · Thyroid Eye Disease Drug: Teprotumumab	Phase 3	Active, closed	2024-07	UK, USA
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) NCT05060016 · ClinicalTrials.gov ↗ · Relapsed/Refractory Small Cell Lung Cancer Drug: Tarlatamab	Phase 2	Active, closed	2021-12	UK, USA
Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity NCT07523711 · ClinicalTrials.gov ↗ · Overweight, Obesity Drug: Maridebart cafraglutide	Phase 1	Active, closed	2026-04	USA
A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease NCT06295679 · ClinicalTrials.gov ↗ · Major Cardiovascular Event, Established Atherosclerotic Cardiovascular Disease	Observational	Active, closed	2022-12	China
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). NCT06333951 · ClinicalTrials.gov ↗ · Thoracic Tumors, Non-small Cell Lung Cancer Drugs: Anvumetostat, Carboplatin, Paclitaxel	Phase 1	Active, closed	2024-09	USA, China
A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus NCT07160257 · ClinicalTrials.gov ↗ · Type 2 Diabetes Mellitus Drug: Maridebart cafraglutide	Phase 1	Active, closed	2025-08	USA
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) NCT07005128 · ClinicalTrials.gov ↗ · Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer Drugs: Carboplatin, Durvalumab, Etoposide	Phase 3	Active, closed	2025-08	USA, China
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) NCT05361395 · ClinicalTrials.gov ↗ · Extensive Stage Small Cell Lung Cancer Drugs: Atezolizumab, Carboplatin, Durvalumab	Phase 1	Active, closed	2022-08	USA
Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer NCT06555796 · ClinicalTrials.gov ↗ · Prostate Cancer, High-risk Biochemical Recurrence, High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer Drug: Xaluritamig	Phase 1	Active, closed	2024-09	USA
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) NCT06898957 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Drugs: Durvalumab, Serplulimab, Tarlatamab	Phase 1	Active, closed	2025-05	USA, China
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia NCT07134088 · ClinicalTrials.gov ↗ · Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia Drug: Blinatumomab	Phase 1/2	Active, closed	2025-12	USA
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma NCT06054555 · ClinicalTrials.gov ↗ · Melanoma Drug: Nivolumab	Phase 3	Active, closed	2023-11	USA, China
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) NCT06700343 · ClinicalTrials.gov ↗ · Relapsing-remitting Multiple Sclerosis (RRMS) Drug: Ocrelizumab	Phase 3	Active, closed	2025-01	USA
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose. NCT07545226 · ClinicalTrials.gov ↗ · Healthy Participants	Phase 1	Active, closed	2026-04	USA
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL NCT04521231 · ClinicalTrials.gov ↗ · B Cell Precursor Acute Lymphoblastic Leukemia Drug: Blinatumomab	Phase 1/2	Active, closed	2021-01	USA, China
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy NCT07225686 · ClinicalTrials.gov ↗ · Obesity, Obstructive Sleep Apnea Drug: Maridebart cafraglutide	Phase 3	Active, closed	2025-12	USA
Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity NCT06585462 · ClinicalTrials.gov ↗ · Cardiometabolic Disease	Phase 1	Active, closed	2024-09	USA
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer NCT03937154 · ClinicalTrials.gov ↗ · Chemotherapy-induced Thrombocytopenia Drug: Romiplostim	Phase 3	Active, closed	2020-02	USA
Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) NCT06180278 · ClinicalTrials.gov ↗ · Neuromyelitis Optica Spectrum Disorder Drugs: Inebilizumab, Uplizna	Phase 4	Active, closed	2024-04	USA, China
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease NCT06401044 · ClinicalTrials.gov ↗ · Thyroid Eye Disease Drug: AMG 732	Phase 1/2	Active, closed	2024-05	USA
Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment NCT06502977 · ClinicalTrials.gov ↗ · Extensive Stage Small Cell Lung Cancer	Phase 2	Active, closed	2024-08	China
Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone NCT04586660 · ClinicalTrials.gov ↗ · Giant Cell Tumor of Bone	Phase 4	Active, closed	2023-08	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Amgen in the EU trials register (CTIS)

11 trials · 1 in Ireland

Authorised or ongoing trials in the EU Clinical Trials Information System with Amgen as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

Study	Phase	Status	Countries
A Double-blind, Randomized,Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants with Elevated Lipoprotein(a) 2025-520554-11-00 · CTIS ↗ · Cardiovascular Diseases	Phase 3	Authorised	Ireland + 16 more
A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants with Obesity or Overweight 2026-525408-82-00 · Nutritional and Metabolic Diseases Drug: Maridebart cafraglutide	Phase 3	Authorised	Czechia, Poland, Denmark + 4 more
A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants with Obesity or Overweight with Type 2 Diabetes Mellitus 2025-524788-19-00 · Nutritional and Metabolic Diseases Drug: Maridebart cafraglutide	Phase 3	Authorised	Germany, Hungary, Czechia + 3 more
A Phase 2/3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study Of Inebilizumab In Participants With Autoimmune Hepatitis 2025-522393-37-00 · Digestive System Diseases Drug: Inebilizumab	Phase 3	Authorised	Belgium, Germany, Hungary + 9 more
A Phase 3, Open-Label, Multicenter, Randomized Study of Subcutaneous vs Intravenous Tarlatamab in Participants with Relapsed Extensive-Stage Small Cell Lung Cancer After Platinum-based First-line chemotherapy (DeLLphi-315) 2026-525489-23-00 · Neoplasms Drug: Tarlatamab	Phase 3	Ongoing	Romania, Poland, Germany + 8 more
A Randomized, Double-masked, Comparative Clinical Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 938 8 mg Versus EYLEA® HD (Aflibercept) Delivered via Intravitreal Injection in Participants with Neovascular Age-related Macular Degeneration 2025-523500-72-00 · Eye Diseases Drug: Aflibercept	Phase 3	Ongoing	Slovakia, Latvia, Czechia + 4 more
A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Adults With Previously Untreated Primary Immune Thrombocytopenia (ITP) 2026-525454-11-00 · Hemic and Lymphatic Diseases Drugs: Prednisolone, Romiplostim	Phase 3	Authorised	Spain, Hungary, Germany
Open-label, Uncontrolled, Multicenter Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Children From 2 Years to Less Than 18 Years of Age with Immunoglobulin G4 related Disease (IgG4-RD) 2025-520988-41-00 · CTIS ↗ · Immune System Diseases Drug: Inebilizumab	Phase 2	Ongoing	Greece, Poland, Italy + 1 more
Multicenter, Safety Follow-up Study to Assess Safety of Prior Treatment with Romosozumab in Children and Adolescents with Osteogenesis Imperfecta 2023-503293-21-00 · CTIS ↗ · Skin and Connective Tissue Diseases Drug: Romosozumab	Phase 3	Ongoing	Germany, Hungary, Italy + 4 more
A Phase 1b/2 Study to Investigate the Safety, Efficacy and Pharmacokinetics of Administration of Subcutaneous (SC) Blinatumomab in Pediatric Participants with Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+) B Cell Precursor Acute Lymphoblastic Leukemia (B-ALL) 2025-521671-31-00 · CTIS ↗ · Neoplasms	Phase 1	Authorised	France, Netherlands, Italy
A Phase 2 Open-label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children From 2 Years to less than 18 Years of age With Generalized Myasthenia Gravis (gMG) 2025-520993-20-00 · CTIS ↗ · Nervous System Diseases Drug: Inebilizumab	Phase 2	Ongoing	Spain, Italy, Poland + 1 more

Drugs in Amgen trials

59 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 19 more in the trial list above.

Conditions in Amgen trials

88 conditions

Obesity7 Overweight4 Small Cell Lung Cancer4 Extensive Stage Small Cell Lung Cancer4 Neuromyelitis Optica Spectrum Disorder3Thyroid Eye Disease3Prostate Cancer3Cardiovascular Disease3Small Cell Lung Cancer (SCLC)2 Metastatic Castration-resistant Prostate Cancer2Atherosclerotic Cardiovascular Disease2Osteogenesis Imperfecta2Advanced Solid Tumors2 Migraine2Secondary Hyperparathyroidism2Diabetes Mellitus, Type 22 Healthy Participants2 Obstructive Sleep Apnea2 Extensive-Stage Small-Cell Lung Cancer1 Small-Cell Lung Cancer1 IgG4 Related Disease1Sjögren's Syndrome1Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer1Active Juvenile Psoriatic Arthritis1

By trial register

Register	Trials	Recruiting
Clinical trials in USA	84	39
Clinical trials in China	36	10
Clinical trials in UK	32	12
Clinical trials in Ireland	3	0
Clinical trials in India	3	1
EU register (CTIS)	11	—

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Obesity

Sponsor	Trials
Eli Lilly and Company	39
Novo Nordisk	39
China-Japan Friendship Hospital	6
Kailera	5
Innovent Biologics (Suzhou)	5
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	4
Hangzhou Sciwind Biosciences	4
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics	3
Peking University Third Hospital	3
Chinese Academy of Sciences	3

Sponsors with the most current trials registered for this condition.

Questions about Amgen trials

How many clinical trials does Amgen sponsor?

Amgen is the lead sponsor of 93 current trials on ClinicalTrials.gov in our USA, China, UK, Ireland and India registers, and 11 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Amgen trials recruiting?

Yes. 42 of its 93 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Amgen testing?

Its current trials name 59 drugs and biologicals as interventions. The most frequent are Maridebart cafraglutide (15), Tarlatamab (14), Inebilizumab (11), Xaluritamig (8) and Pembrolizumab (6). The number in brackets is how many of its trials name each drug.

Does Amgen have clinical trials in Ireland?

Yes. 3 trials in our Ireland register (ClinicalTrials.gov), and 1 trial in the EU register (CTIS) with a site in Ireland. Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Amgen clinical trials